Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Fact Sheet
Feb 4, 2022
| Erica Klinger
Cancer Patients Save $16 Billion Per Year with Generics and Biosimilars
Press Release
Feb 2, 2022
| Rachel Schwartz
AAM Statement on FDA User Fee Reauthorization
Fact Sheet
Jan 26, 2022
| Erica Klinger
BsUFA Reauthorization: A Primer
Fact Sheet
Jan 26, 2022
| Erica Klinger
GDUFA Reauthorization: A Primer
Blog
Jan 26, 2022
| Monét Stanford
Generic Prices Are Falling, But Seniors Are Paying More for Generic Drugs. What’s Happening Here?
Press Release
Jan 24, 2022
| Rachel Schwartz
Avalere Analysis Finds Medicare Part D Patients Continue to Pay More for Generics
Fact Sheet
Jan 12, 2022
| Erica Klinger
Generics and Biosimilar Medicines Deliver More Savings Every Year
Video
Jan 5, 2022
| Erica Klinger
Join Us at Access! 2022 in Orlando, Florida!
Blog
Jan 4, 2022
| Dan Leonard
AAM All Access Podcast: Bob Billings
Blog
Dec 20, 2021
| Craig Burton
Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
Blog
Dec 14, 2021
| Bob Billings
Thank you, Ramprasad Reddy
Blog
Dec 3, 2021
| Craig Burton
The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action